Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human BCR Antibodies:
anti-Mouse (Murine) BCR Antibodies:
anti-Rat (Rattus) BCR Antibodies:
Go to our pre-filtered search.
Human Monoclonal BCR Primary Antibody for IA, IF - ABIN2192147
Bruynzeel, Abou El Hassan, Schalkwijk, Berkhof, Bast, Niessen, van der Vijgh: Anti-inflammatory agents and monoHER protect against DOX-induced cardiotoxicity and accumulation of CML in mice. in British journal of cancer 2007
Show all 5 Pubmed References
Human BCR Primary Antibody for IHC - ABIN965655
Sattler, Verma, Byrne, Shrikhande, Winkler, Algate, Rohrschneider, Griffin: BCR/ABL directly inhibits expression of SHIP, an SH2-containing polyinositol-5-phosphatase involved in the regulation of hematopoiesis. in Molecular and cellular biology 1999
Data indicate the Sp1 (show PSG1 Antibodies) oncogene (show RAB1A Antibodies) functions as a positive regulator for BCR/ABL (show ABL1 Antibodies) expression.
dehydrocostus lactone significantly inhibits the phosphorylation expression of Bcr/Abl (show ABL1 Antibodies), STAT5 (show STAT5A Antibodies), JAK2 (show JAK2 Antibodies), and STAT3 (show STAT3 Antibodies) and downstream molecules including p-CrkL (show CRKL Antibodies), Mcl-1 (show MCL1 Antibodies), Bcl-XL (show BCL2L1 Antibodies), and Bcl-2 (show BCL2 Antibodies) proteins in K562 cells.
H19 (show NCKAP1 Antibodies) overexpression, a frequent event in chronic myeloid leukemia (show BCL11A Antibodies), was associated with higher BCR-ABL (show ABL1 Antibodies) transcript and disease progression. H19 (show NCKAP1 Antibodies) DMR (show WDR20 Antibodies)/ICR hypomethylation in CML may be one of the mechanisms mediating H19 (show NCKAP1 Antibodies) overexpression.
Frequent molecular monitoring and intervention are required for patients who do not show a reduction in BCR-ABL1 (show ABL1 Antibodies) transcripts to these levels after stem cell transplantation.
this study shows that BCR regulates inflammation development via the alpha subunit of casein kinase II (show CSNK2A1 Antibodies) associated with BCR
the e13a2 BCR-ABL1 (show ABL1 Antibodies) fusion transcript affects the rate, the depth, and the speed of the response to treatment with imatinib firstline, and that including the transcript type in the calculation of the baseline risk scores may improve prognostic stratification and may help the choice of the best treatment policy.
6 overexpression may contribute to the high proliferation and low apoptosis in chronic myeloid leukemia (show BCL11A Antibodies) cells and can be regulated by BCR/ABL (show ABL1 Antibodies) signal transduction through downstream phosphoinositide 3-kinase/Akt (show AKT1 Antibodies) and Janus kinase/signal transducer and activator of transcription (show STAT1 Antibodies) pathways, suggesting cell division cycle protein 6 as a potential therapeutic target in chronic myeloid leukemia (show BCL11A Antibodies).
though our data support the previous findings that co-expression of BCR-ABL transcripts is due to the occurrence of exonic and intronic polymorphisms in the BCR gene, it also shows that the intronic polymorphism can arise without the linked exonic polymorphism. The occurrence of ABL kinase domain mutation is less frequent in Indian population.
In silico three-dimensional modeling of apoptin, molecular docking experiments between apoptin model and the known structure of Bcr-Abl (show ABL1 Antibodies), and the 3D structures of SH2 domains of CrkL (show CRKL Antibodies) and Bcr-Abl (show ABL1 Antibodies), were performed.
The present study screened for the presence of bcr-abl (show ABL1 Antibodies) transcripts in the blood of a group of healthy individuals.
BCR signaling elicits maximal cell death through upregulation of multiple BH3-only (show BBC3 Antibodies) proteins; namely Bim (show BCL2L11 Antibodies), Bik (show BIK Antibodies), and Noxa (show PMAIP1 Antibodies).
The resistance in BCR-ABL1 (show ABL1 Antibodies) cells resulted either from the Y253H mutation in the BCR-ABL1 (show ABL1 Antibodies) gene or incubation in increasing concentrations of imatinib.
PDZK1 (show PDZK1 Antibodies) has novel SR-BI (show SCARB1 Antibodies)-independent function in VSM that affords protection from neointima formation, and this involves PDZK1 (show PDZK1 Antibodies) suppression of VSM cell proliferation via an inhibitory interaction with Bcr
Hap1 (show HAP1 Antibodies) interacts with Bcr on microtubules to regulate neuronal differentiation.
Grb10 (show GRB10 Antibodies) is involved in BCR-ABL (show ABL1 Antibodies)-positive leukemia in mice.
Bcr is an integral member of the Par (show AFG3L2 Antibodies)-Tiam1 (show TIAM1 Antibodies) complex that controls polarized cell migration by locally restricting both Rac1 and PKCzeta (show PRKCZ Antibodies) function.
Loss of Bcr expression causes defects in spine development.
Suggest that HS-438 may be a novel drug candidate with the therapeutic potential to target BCR-ABL (show ABL1 Antibodies) and overcome imatinib resistance in patients with chronic myeloid leukemia (show BCL11A Antibodies).
IRF8 (show IRF8 Antibodies)-rescued BCR-ABL (show ABL1 Antibodies)-expressing dendritic cells were capable of inducing CTLs more efficiently than control dendritic cells.
study provided evidence for a novel, BCR-ABL (show ABL1 Antibodies)-mediated antiapoptotic mechanism, which results from the increased acetylation of p53 (show TP53 Antibodies) at the K317/K320 residue, thus preventing the nuclear export of p53 (show TP53 Antibodies) in response to DNA damage.
A reciprocal translocation between chromosomes 22 and 9 produces the Philadelphia chromosome, which is often found in patients with chronic myelogenous leukemia. The chromosome 22 breakpoint for this translocation is located within the BCR gene. The translocation produces a fusion protein which is encoded by sequence from both BCR and ABL, the gene at the chromosome 9 breakpoint. Although the BCR-ABL fusion protein has been extensively studied, the function of the normal BCR gene product is not clear. The protein has serine/threonine kinase activity and is a GTPase-activating protein for p21rac. Two transcript variants encoding different isoforms have been found for this gene.
breakpoint cluster region
, breakpoint cluster region protein-like
, BCR/FGFR1 chimera protein
, FGFR1/BCR chimera protein
, breakpoint cluster region protein
, renal carcinoma antigen NY-REN-26
, breakpoint cluster region homolog